Summary
Generic injectables refer to sterile solutions (including emulsions and suspensions) made of drugs for injection into the body, and sterile powders or concentrated solutions that are prepared into solutions or suspensions before use.
The injection is fast and reliable, not affected by pH, enzymes, food, etc., has no first-pass effect, and can play a systemic or local positioning effect. It is suitable for patients who are not suitable for oral medicine and patients who cannot be taken orally. However, the development and production process of injections is complicated and safe. The body has poor adaptability and high cost.
According to APO Research, The global Generic Injectables market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Generic Injectables is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Generic Injectables is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Generic Injectables is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Generic Injectables is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global companies of Generic Injectables include Hospira (Pfizer Inc.), Fresenius Kabi, Sandoz (Novartis), Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd, Grifols, Nichi-Iko Group (Sagent), Teva Pharmaceutical and Auromedics, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Generic Injectables, market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Generic Injectables, also provides the revenue of main regions and countries. Of the upcoming market potential for Generic Injectables, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Generic Injectables revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Generic Injectables market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Generic Injectables revenue, projected growth trends, production technology, application and end-user industry.
Generic Injectables segment by Company
Hospira (Pfizer Inc.)
Fresenius Kabi
Sandoz (Novartis)
Hikma Pharmaceuticals PLC
Dr. Reddy’s Laboratories Ltd
Grifols
Nichi-Iko Group (Sagent)
Teva Pharmaceutical
Auromedics
Sanofi
Gland Pharma
Endo International PLC
Generic Injectables segment by Type
Small Molecule
Large Molecule
Generic Injectables segment by Application
Oncology
Anesthesia
Anti-Infectives
Parenteral Nutrition
Cardiovascular Diseases
Generic Injectables segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Generic Injectables market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Generic Injectables and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Generic Injectables.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Generic Injectables in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Generic Injectables company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Generic Injectables revenue, gross margin, and recent development, etc.
Chapter 8: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: Middle East, Africa, and Latin America type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
1 Market Overview
1.1 Product Definition
1.2 Generic Injectables Market by Type
1.2.1 Global Generic Injectables Market Size by Type, 2019 VS 2023 VS 2030
1.2.2 Small Molecule
1.2.3 Large Molecule
1.3 Generic Injectables Market by Application
1.3.1 Global Generic Injectables Market Size by Application, 2019 VS 2023 VS 2030
1.3.2 Oncology
1.3.3 Anesthesia
1.3.4 Anti-Infectives
1.3.5 Parenteral Nutrition
1.3.6 Cardiovascular Diseases
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Generic Injectables Market Dynamics
2.1 Generic Injectables Industry Trends
2.2 Generic Injectables Industry Drivers
2.3 Generic Injectables Industry Opportunities and Challenges
2.4 Generic Injectables Industry Restraints
3 Global Growth Perspective
3.1 Global Generic Injectables Market Perspective (2019-2030)
3.2 Global Generic Injectables Growth Trends by Region
3.2.1 Global Generic Injectables Market Size by Region: 2019 VS 2023 VS 2030
3.2.2 Global Generic Injectables Market Size by Region (2019-2024)
3.2.3 Global Generic Injectables Market Size by Region (2025-2030)
4 Competitive Landscape by Players
4.1 Global Generic Injectables Revenue by Players
4.1.1 Global Generic Injectables Revenue by Players (2019-2024)
4.1.2 Global Generic Injectables Revenue Market Share by Players (2019-2024)
4.1.3 Global Generic Injectables Players Revenue Share Top 10 and Top 5 in 2023
4.2 Global Generic Injectables Key Players Ranking, 2022 VS 2023 VS 2024
4.3 Global Generic Injectables Key Players Headquarters & Area Served
4.4 Global Generic Injectables Players, Product Type & Application
4.5 Global Generic Injectables Players Commercialization Time
4.6 Market Competitive Analysis
4.6.1 Global Generic Injectables Market CR5 and HHI
4.6.2 Global Top 5 and 10 Generic Injectables Players Market Share by Revenue in 2023
4.6.3 2023 Generic Injectables Tier 1, Tier 2, and Tier 3
5 Generic Injectables Market Size by Type
5.1 Global Generic Injectables Revenue by Type (2019 VS 2023 VS 2030)
5.2 Global Generic Injectables Revenue by Type (2019-2030)
5.3 Global Generic Injectables Revenue Market Share by Type (2019-2030)
6 Generic Injectables Market Size by Application
6.1 Global Generic Injectables Revenue by Application (2019 VS 2023 VS 2030)
6.2 Global Generic Injectables Revenue by Application (2019-2030)
6.3 Global Generic Injectables Revenue Market Share by Application (2019-2030)
7 Company Profiles
7.1 Hospira (Pfizer Inc.)
7.1.1 Hospira (Pfizer Inc.) Comapny Information
7.1.2 Hospira (Pfizer Inc.) Business Overview
7.1.3 Hospira (Pfizer Inc.) Generic Injectables Revenue and Gross Margin (2019-2024)
7.1.4 Hospira (Pfizer Inc.) Generic Injectables Product Portfolio
7.1.5 Hospira (Pfizer Inc.) Recent Developments
7.2 Fresenius Kabi
7.2.1 Fresenius Kabi Comapny Information
7.2.2 Fresenius Kabi Business Overview
7.2.3 Fresenius Kabi Generic Injectables Revenue and Gross Margin (2019-2024)
7.2.4 Fresenius Kabi Generic Injectables Product Portfolio
7.2.5 Fresenius Kabi Recent Developments
7.3 Sandoz (Novartis)
7.3.1 Sandoz (Novartis) Comapny Information
7.3.2 Sandoz (Novartis) Business Overview
7.3.3 Sandoz (Novartis) Generic Injectables Revenue and Gross Margin (2019-2024)
7.3.4 Sandoz (Novartis) Generic Injectables Product Portfolio
7.3.5 Sandoz (Novartis) Recent Developments
7.4 Hikma Pharmaceuticals PLC
7.4.1 Hikma Pharmaceuticals PLC Comapny Information
7.4.2 Hikma Pharmaceuticals PLC Business Overview
7.4.3 Hikma Pharmaceuticals PLC Generic Injectables Revenue and Gross Margin (2019-2024)
7.4.4 Hikma Pharmaceuticals PLC Generic Injectables Product Portfolio
7.4.5 Hikma Pharmaceuticals PLC Recent Developments
7.5 Dr. Reddy’s Laboratories Ltd
7.5.1 Dr. Reddy’s Laboratories Ltd Comapny Information
7.5.2 Dr. Reddy’s Laboratories Ltd Business Overview
7.5.3 Dr. Reddy’s Laboratories Ltd Generic Injectables Revenue and Gross Margin (2019-2024)
7.5.4 Dr. Reddy’s Laboratories Ltd Generic Injectables Product Portfolio
7.5.5 Dr. Reddy’s Laboratories Ltd Recent Developments
7.6 Grifols
7.6.1 Grifols Comapny Information
7.6.2 Grifols Business Overview
7.6.3 Grifols Generic Injectables Revenue and Gross Margin (2019-2024)
7.6.4 Grifols Generic Injectables Product Portfolio
7.6.5 Grifols Recent Developments
7.7 Nichi-Iko Group (Sagent)
7.7.1 Nichi-Iko Group (Sagent) Comapny Information
7.7.2 Nichi-Iko Group (Sagent) Business Overview
7.7.3 Nichi-Iko Group (Sagent) Generic Injectables Revenue and Gross Margin (2019-2024)
7.7.4 Nichi-Iko Group (Sagent) Generic Injectables Product Portfolio
7.7.5 Nichi-Iko Group (Sagent) Recent Developments
7.8 Teva Pharmaceutical
7.8.1 Teva Pharmaceutical Comapny Information
7.8.2 Teva Pharmaceutical Business Overview
7.8.3 Teva Pharmaceutical Generic Injectables Revenue and Gross Margin (2019-2024)
7.8.4 Teva Pharmaceutical Generic Injectables Product Portfolio
7.8.5 Teva Pharmaceutical Recent Developments
7.9 Auromedics
7.9.1 Auromedics Comapny Information
7.9.2 Auromedics Business Overview
7.9.3 Auromedics Generic Injectables Revenue and Gross Margin (2019-2024)
7.9.4 Auromedics Generic Injectables Product Portfolio
7.9.5 Auromedics Recent Developments
7.10 Sanofi
7.10.1 Sanofi Comapny Information
7.10.2 Sanofi Business Overview
7.10.3 Sanofi Generic Injectables Revenue and Gross Margin (2019-2024)
7.10.4 Sanofi Generic Injectables Product Portfolio
7.10.5 Sanofi Recent Developments
7.11 Gland Pharma
7.11.1 Gland Pharma Comapny Information
7.11.2 Gland Pharma Business Overview
7.11.3 Gland Pharma Generic Injectables Revenue and Gross Margin (2019-2024)
7.11.4 Gland Pharma Generic Injectables Product Portfolio
7.11.5 Gland Pharma Recent Developments
7.12 Endo International PLC
7.12.1 Endo International PLC Comapny Information
7.12.2 Endo International PLC Business Overview
7.12.3 Endo International PLC Generic Injectables Revenue and Gross Margin (2019-2024)
7.12.4 Endo International PLC Generic Injectables Product Portfolio
7.12.5 Endo International PLC Recent Developments
8 North America
8.1 North America Generic Injectables Revenue (2019-2030)
8.2 North America Generic Injectables Revenue by Type (2019-2030)
8.2.1 North America Generic Injectables Revenue by Type (2019-2024)
8.2.2 North America Generic Injectables Revenue by Type (2025-2030)
8.3 North America Generic Injectables Revenue Share by Type (2019-2030)
8.4 North America Generic Injectables Revenue by Application (2019-2030)
8.4.1 North America Generic Injectables Revenue by Application (2019-2024)
8.4.2 North America Generic Injectables Revenue by Application (2025-2030)
8.5 North America Generic Injectables Revenue Share by Application (2019-2030)
8.6 North America Generic Injectables Revenue by Country
8.6.1 North America Generic Injectables Revenue by Country (2019 VS 2023 VS 2030)
8.6.2 North America Generic Injectables Revenue by Country (2019-2024)
8.6.3 North America Generic Injectables Revenue by Country (2025-2030)
8.6.4 United States
8.6.5 Canada
9 Europe
9.1 Europe Generic Injectables Revenue (2019-2030)
9.2 Europe Generic Injectables Revenue by Type (2019-2030)
9.2.1 Europe Generic Injectables Revenue by Type (2019-2024)
9.2.2 Europe Generic Injectables Revenue by Type (2025-2030)
9.3 Europe Generic Injectables Revenue Share by Type (2019-2030)
9.4 Europe Generic Injectables Revenue by Application (2019-2030)
9.4.1 Europe Generic Injectables Revenue by Application (2019-2024)
9.4.2 Europe Generic Injectables Revenue by Application (2025-2030)
9.5 Europe Generic Injectables Revenue Share by Application (2019-2030)
9.6 Europe Generic Injectables Revenue by Country
9.6.1 Europe Generic Injectables Revenue by Country (2019 VS 2023 VS 2030)
9.6.2 Europe Generic Injectables Revenue by Country (2019-2024)
9.6.3 Europe Generic Injectables Revenue by Country (2025-2030)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
10 China
10.1 China Generic Injectables Revenue (2019-2030)
10.2 China Generic Injectables Revenue by Type (2019-2030)
10.2.1 China Generic Injectables Revenue by Type (2019-2024)
10.2.2 China Generic Injectables Revenue by Type (2025-2030)
10.3 China Generic Injectables Revenue Share by Type (2019-2030)
10.4 China Generic Injectables Revenue by Application (2019-2030)
10.4.1 China Generic Injectables Revenue by Application (2019-2024)
10.4.2 China Generic Injectables Revenue by Application (2025-2030)
10.5 China Generic Injectables Revenue Share by Application (2019-2030)
11 Asia (Excluding China)
11.1 Asia Generic Injectables Revenue (2019-2030)
11.2 Asia Generic Injectables Revenue by Type (2019-2030)
11.2.1 Asia Generic Injectables Revenue by Type (2019-2024)
11.2.2 Asia Generic Injectables Revenue by Type (2025-2030)
11.3 Asia Generic Injectables Revenue Share by Type (2019-2030)
11.4 Asia Generic Injectables Revenue by Application (2019-2030)
11.4.1 Asia Generic Injectables Revenue by Application (2019-2024)
11.4.2 Asia Generic Injectables Revenue by Application (2025-2030)
11.5 Asia Generic Injectables Revenue Share by Application (2019-2030)
11.6 Asia Generic Injectables Revenue by Country
11.6.1 Asia Generic Injectables Revenue by Country (2019 VS 2023 VS 2030)
11.6.2 Asia Generic Injectables Revenue by Country (2019-2024)
11.6.3 Asia Generic Injectables Revenue by Country (2025-2030)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 China Taiwan
11.6.9 Southeast Asia
12 Middle East, Africa, Latin America
12.1 MEALA Generic Injectables Revenue (2019-2030)
12.2 MEALA Generic Injectables Revenue by Type (2019-2030)
12.2.1 MEALA Generic Injectables Revenue by Type (2019-2024)
12.2.2 MEALA Generic Injectables Revenue by Type (2025-2030)
12.3 MEALA Generic Injectables Revenue Share by Type (2019-2030)
12.4 MEALA Generic Injectables Revenue by Application (2019-2030)
12.4.1 MEALA Generic Injectables Revenue by Application (2019-2024)
12.4.2 MEALA Generic Injectables Revenue by Application (2025-2030)
12.5 MEALA Generic Injectables Revenue Share by Application (2019-2030)
12.6 MEALA Generic Injectables Revenue by Country
12.6.1 MEALA Generic Injectables Revenue by Country (2019 VS 2023 VS 2030)
12.6.2 MEALA Generic Injectables Revenue by Country (2019-2024)
12.6.3 MEALA Generic Injectables Revenue by Country (2025-2030)
12.6.4 Mexico
12.6.5 Brazil
12.6.6 Israel
12.6.7 Argentina
12.6.8 Colombia
12.6.9 Turkey
12.6.10 Saudi Arabia
12.6.11 UAE
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
List of Tables
Table 1. Global Generic Injectables Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Table 1. Small Molecule Major Manufacturers
Table 2. Large Molecule Major Manufacturers
Table 3. Global Generic Injectables Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Table 4. Oncology Major Manufacturers
Table 5. Anesthesia Major Manufacturers
Table 6. Anti-Infectives Major Manufacturers
Table 7. Parenteral Nutrition Major Manufacturers
Table 8. Cardiovascular Diseases Major Manufacturers
Table 9. Generic Injectables Industry Trends
Table 10. Generic Injectables Industry Drivers
Table 11. Generic Injectables Industry Opportunities and Challenges
Table 12. Generic Injectables Industry Restraints
Table 13. Global Generic Injectables Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
Table 14. Global Generic Injectables Market Size by Region (2019-2024) & (US$ Million)
Table 15. Global Generic Injectables Market Share by Region (2019-2024)
Table 16. Global Generic Injectables Market Size by Region (2025-2030) & (US$ Million)
Table 17. Global Generic Injectables Market Share by Region (2025-2030)
Table 18. Global Generic Injectables Revenue by Players (US$ Million) & (2019-2024)
Table 19. Global Generic Injectables Revenue Market Share by Players (2019-2024)
Table 20. Global Generic Injectables Key Players Ranking, 2022 VS 2023 VS 2024
Table 21. Global Generic Injectables Key Players Headquarters & Area Served
Table 22. Global Generic Injectables Players, Product Type & Application
Table 23. Global Generic Injectables Players Commercialization Time
Table 24. Global Players Market Concentration Ratio (CR5 and HHI)
Table 25. Global Generic Injectables by Players Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)
Table 26. Global Generic Injectables Revenue by Type 2019 VS 2023 VS 2030 (US$ Million)
Table 27. Global Generic Injectables Revenue by Type (2019-2024) & (US$ Million)
Table 28. Global Generic Injectables Revenue by Type (2025-2030) & (US$ Million)
Table 29. Global Generic Injectables Revenue Market Share by Type (2019-2024) & (US$ Million)
Table 30. Global Generic Injectables Revenue Market Share by Type (2025-2030) & (US$ Million)
Table 31. Global Generic Injectables Revenue by Application 2019 VS 2023 VS 2030 (US$ Million)
Table 32. Global Generic Injectables Revenue by Application (2019-2024) & (US$ Million)
Table 33. Global Generic Injectables Revenue by Application (2025-2030) & (US$ Million)
Table 34. Global Generic Injectables Revenue Market Share by Application (2019-2024) & (US$ Million)
Table 35. Global Generic Injectables Revenue Market Share by Application (2025-2030) & (US$ Million)
Table 36. Hospira (Pfizer Inc.) Company Information
Table 37. Hospira (Pfizer Inc.) Business Overview
Table 38. Hospira (Pfizer Inc.) Generic Injectables Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 39. Hospira (Pfizer Inc.) Generic Injectables Product Portfolio
Table 40. Hospira (Pfizer Inc.) Recent Development
Table 41. Fresenius Kabi Company Information
Table 42. Fresenius Kabi Business Overview
Table 43. Fresenius Kabi Generic Injectables Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 44. Fresenius Kabi Generic Injectables Product Portfolio
Table 45. Fresenius Kabi Recent Development
Table 46. Sandoz (Novartis) Company Information
Table 47. Sandoz (Novartis) Business Overview
Table 48. Sandoz (Novartis) Generic Injectables Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 49. Sandoz (Novartis) Generic Injectables Product Portfolio
Table 50. Sandoz (Novartis) Recent Development
Table 51. Hikma Pharmaceuticals PLC Company Information
Table 52. Hikma Pharmaceuticals PLC Business Overview
Table 53. Hikma Pharmaceuticals PLC Generic Injectables Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 54. Hikma Pharmaceuticals PLC Generic Injectables Product Portfolio
Table 55. Hikma Pharmaceuticals PLC Recent Development
Table 56. Dr. Reddy’s Laboratories Ltd Company Information
Table 57. Dr. Reddy’s Laboratories Ltd Business Overview
Table 58. Dr. Reddy’s Laboratories Ltd Generic Injectables Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 59. Dr. Reddy’s Laboratories Ltd Generic Injectables Product Portfolio
Table 60. Dr. Reddy’s Laboratories Ltd Recent Development
Table 61. Grifols Company Information
Table 62. Grifols Business Overview
Table 63. Grifols Generic Injectables Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 64. Grifols Generic Injectables Product Portfolio
Table 65. Grifols Recent Development
Table 66. Nichi-Iko Group (Sagent) Company Information
Table 67. Nichi-Iko Group (Sagent) Business Overview
Table 68. Nichi-Iko Group (Sagent) Generic Injectables Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 69. Nichi-Iko Group (Sagent) Generic Injectables Product Portfolio
Table 70. Nichi-Iko Group (Sagent) Recent Development
Table 71. Teva Pharmaceutical Company Information
Table 72. Teva Pharmaceutical Business Overview
Table 73. Teva Pharmaceutical Generic Injectables Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 74. Teva Pharmaceutical Generic Injectables Product Portfolio
Table 75. Teva Pharmaceutical Recent Development
Table 76. Auromedics Company Information
Table 77. Auromedics Business Overview
Table 78. Auromedics Generic Injectables Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 79. Auromedics Generic Injectables Product Portfolio
Table 80. Auromedics Recent Development
Table 81. Sanofi Company Information
Table 82. Sanofi Business Overview
Table 83. Sanofi Generic Injectables Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 84. Sanofi Generic Injectables Product Portfolio
Table 85. Sanofi Recent Development
Table 86. Gland Pharma Company Information
Table 87. Gland Pharma Business Overview
Table 88. Gland Pharma Generic Injectables Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 89. Gland Pharma Generic Injectables Product Portfolio
Table 90. Gland Pharma Recent Development
Table 91. Endo International PLC Company Information
Table 92. Endo International PLC Business Overview
Table 93. Endo International PLC Generic Injectables Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 94. Endo International PLC Generic Injectables Product Portfolio
Table 95. Endo International PLC Recent Development
Table 96. North America Generic Injectables Revenue by Type (2019-2024) & (US$ Million)
Table 97. North America Generic Injectables Revenue by Application (2019-2024) & (US$ Million)
Table 98. North America Generic Injectables Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 99. North America Generic Injectables Revenue by Country (2019-2024) & (US$ Million)
Table 100. North America Generic Injectables Revenue by Country (2025-2030) & (US$ Million)
Table 101. Europe Generic Injectables Revenue by Type (2019-2024) & (US$ Million)
Table 102. Europe Generic Injectables Revenue by Application (2019-2024) & (US$ Million)
Table 103. Europe Generic Injectables Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 104. Europe Generic Injectables Revenue by Country (2019-2024) & (US$ Million)
Table 105. Europe Generic Injectables Revenue by Country (2025-2030) & (US$ Million)
Table 106. China Generic Injectables Revenue by Type (2019-2024) & (US$ Million)
Table 107. China Generic Injectables Revenue by Application (2019-2024) & (US$ Million)
Table 108. Asia Generic Injectables Revenue by Type (2019-2024) & (US$ Million)
Table 109. Asia Generic Injectables Revenue by Application (2019-2024) & (US$ Million)
Table 110. Asia Generic Injectables Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 111. Asia Generic Injectables Revenue by Country (2019-2024) & (US$ Million)
Table 112. Asia Generic Injectables Revenue by Country (2025-2030) & (US$ Million)
Table 113. MEALA Generic Injectables Revenue by Type (2019-2024) & (US$ Million)
Table 114. MEALA Generic Injectables Revenue by Application (2019-2024) & (US$ Million)
Table 115. MEALA Generic Injectables Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 116. MEALA Generic Injectables Revenue by Country (2019-2024) & (US$ Million)
Table 117. MEALA Generic Injectables Revenue by Country (2025-2030) & (US$ Million)
Table 118. Research Programs/Design for This Report
Table 119. Authors List of This Report
Table 120. Secondary Sources
Table 121. Primary Sources
List of Figures
Figure 1. Generic Injectables Product Picture
Figure 2. Global Generic Injectables Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global Generic Injectables Market Size Share 2019 VS 2023 VS 2030
Figure 4. Small Molecule Picture
Figure 5. Large Molecule Picture
Figure 6. Global Generic Injectables Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Figure 7. Global Generic Injectables Market Size Share 2019 VS 2023 VS 2030
Figure 8. Oncology Picture
Figure 9. Anesthesia Picture
Figure 10. Anti-Infectives Picture
Figure 11. Parenteral Nutrition Picture
Figure 12. Cardiovascular Diseases Picture
Figure 13. Global Generic Injectables Market Size (US$ Million) & (2019-2030)
Figure 14. Global Generic Injectables Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Generic Injectables Market Share by Region: 2019 VS 2023 VS 2030
Figure 16. Global Generic Injectables Players Revenue Share Top 10 and Top 5 in 2023
Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 18. Global Generic Injectables Revenue by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 19. Global Generic Injectables Revenue Market Share 2019 VS 2023 VS 2030
Figure 20. Global Generic Injectables Revenue Market Share by Type (2019-2030)
Figure 21. Global Generic Injectables Revenue by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 22. Global Generic Injectables Revenue Market Share by Application (2019 VS 2023 VS 2030)
Figure 23. Global Generic Injectables Revenue Market Share by Application (2019-2030)
Figure 24. North America Generic Injectables Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 25. North America Generic Injectables Revenue by Type (2025-2030) & (US$ Million)
Figure 26. North America Generic Injectables Revenue Share by Type (2019-2030)
Figure 27. North America Generic Injectables Revenue by Application (2025-2030) & (US$ Million)
Figure 28. North America Generic Injectables Revenue Share by Application (2019-2030)
Figure 29. North America Generic Injectables Revenue Share by Country (2019-2030)
Figure 30. United States Generic Injectables Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 31. Canada Generic Injectables Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 32. Europe Generic Injectables Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 33. Europe Generic Injectables Revenue by Type (2025-2030) & (US$ Million)
Figure 34. Europe Generic Injectables Revenue Share by Type (2019-2030)
Figure 35. Europe Generic Injectables Revenue by Application (2025-2030) & (US$ Million)
Figure 36. Europe Generic Injectables Revenue Share by Application (2019-2030)
Figure 37. Europe Generic Injectables Revenue Share by Country (2019-2030)
Figure 38. Germany Generic Injectables Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 39. France Generic Injectables Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 40. U.K. Generic Injectables Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 41. Italy Generic Injectables Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 42. Russia Generic Injectables Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 43. Nordic Countries Generic Injectables Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 44. China Generic Injectables Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 45. China Generic Injectables Revenue by Type (2025-2030) & (US$ Million)
Figure 46. China Generic Injectables Revenue Share by Type (2019-2030)
Figure 47. China Generic Injectables Revenue by Application (2025-2030) & (US$ Million)
Figure 48. China Generic Injectables Revenue Share by Application (2019-2030)
Figure 49. Asia Generic Injectables Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 50. Asia Generic Injectables Revenue by Type (2025-2030) & (US$ Million)
Figure 51. Asia Generic Injectables Revenue Share by Type (2019-2030)
Figure 52. Asia Generic Injectables Revenue by Application (2025-2030) & (US$ Million)
Figure 53. Asia Generic Injectables Revenue Share by Application (2019-2030)
Figure 54. Asia Generic Injectables Revenue Share by Country (2019-2030)
Figure 55. Japan Generic Injectables Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 56. South Korea Generic Injectables Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 57. India Generic Injectables Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 58. Australia Generic Injectables Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 59. China Taiwan Generic Injectables Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 60. Southeast Asia Generic Injectables Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 61. MEALA Generic Injectables Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 62. MEALA Generic Injectables Revenue by Type (2025-2030) & (US$ Million)
Figure 63. MEALA Generic Injectables Revenue Share by Type (2019-2030)
Figure 64. MEALA Generic Injectables Revenue by Application (2025-2030) & (US$ Million)
Figure 65. MEALA Generic Injectables Revenue Share by Application (2019-2030)
Figure 66. MEALA Generic Injectables Revenue Share by Country (2019-2030)
Figure 67. Mexico Generic Injectables Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 68. South Korea Generic Injectables Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 69. Brazil Generic Injectables Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 70. Israel Generic Injectables Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 71. Argentina Generic Injectables Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 72. Colombia Generic Injectables Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 73. Turkey Generic Injectables Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 74. Saudi Arabia Generic Injectables Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 75. UAE Generic Injectables Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 76. Years Considered
Figure 77. Research Process
Figure 78. Key Executives Interviewed
